BioCentury
ARTICLE | Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

July 1, 2019 11:27 PM UTC

Alnylam submits hepatic porphyria therapy MAA
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) submitted an MAA to EMA for givosiran to treat acute hepatic porphyria. Last month, the biotech completed a rolling NDA for the subcutaneous RNAi therapeutic targeting ALAS-1 in the indication.

Sage launches postpartum therapy
Sage Therapeutics Inc. (NASDAQ:SAGE) has launched its postpartum depression therapy Zulresso brexanolone, according to partner Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Sage priced the drug at $34,000 (see "Sage Broadens the Spotlight on Postpartum Depression")...